Stockscreener 앱 받기
10.12
0.59%
-0.06
전일 마감가:
$10.18
열려 있는:
$10.26
하루 거래량:
161.68K
Relative Volume:
0.08
시가총액:
$1.19B
수익:
$59.61M
순이익/손실:
$-262.14M
주가수익비율:
-1.8267
EPS:
-5.54
순현금흐름:
$-247.49M
1주 성능:
+1.91%
1개월 성능:
+21.78%
6개월 성능:
+6.75%
1년 성능:
+435.45%
1일 변동 폭
$10.03
$10.28
1주일 범위
$8.90
$10.42
52주 변동 폭
$1.76
$13.17
Arcutis Biotherapeutics Inc Stock (ARQT) Company Profile
명칭
Arcutis Biotherapeutics Inc
전화
805-418-5006
주소
3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA
ARQT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| ARQT | 10.13 | 1.19B | 59.61M | -262.14M | -247.49M | -5.54 |
| VRTX | 448.08 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 745.19 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 588.39 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.24 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 103.02 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Arcutis Biotherapeutics Inc Stock (ARQT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-01-03 | 업그레이드 | Mizuho | Neutral → Buy |
| 2023-10-26 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2023-10-13 | 다운그레이드 | Goldman | Buy → Neutral |
| 2022-09-07 | 개시 | Needham | Buy |
| 2022-03-17 | 개시 | Goldman | Buy |
| 2021-06-30 | 개시 | Mizuho | Buy |
| 2021-05-27 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-09 | 업그레이드 | Goldman | Neutral → Buy |
| 2020-10-08 | 개시 | Truist | Buy |
| 2020-02-25 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-02-25 | 개시 | Cowen | Outperform |
| 2020-02-25 | 개시 | Goldman | Neutral |
| 2020-02-25 | 개시 | Guggenheim | Buy |
모두보기
Arcutis Biotherapeutics Inc 주식(ARQT)의 최신 뉴스
Arcutis Biotherapeutics SVP sells $17,190 in stock - Investing.com India
Arcutis Biotherapeutics, Inc. (ARQT) Recently Broke Out Above the 200-Day Moving Average - Yahoo Finance
Arcutis Biotherapeutics, Inc. (ARQT) Crossed Above the 50-Day Moving Average: What That Means for Investors - Yahoo Finance
Arcutis Biotherapeutics, Inc. (ARQT) Reports Q3 Loss, Tops Revenue Estimates - MSN
Arcutis Biotherapeutics SVP sells $17,190 in stock By Investing.com - Investing.com Canada
Arcutis Biotherapeutics, Inc. (ARQT) Recently Broke Out Above the 20-Day Moving Average - Zacks Investment Research
Bears are Losing Control Over Arcutis Biotherapeutics (ARQT), Here's Why It's a 'Buy' Now - Yahoo Finance
Arcutis Biotherapeutics SVP sells shares worth $712,620 - Investing.com
Arcutis Biotherapeutics SVP sells shares worth $712,620 By Investing.com - Investing.com UK
Arcutis Biotherapeutics: What Lies Ahead (NASDAQ:ARQT) - Seeking Alpha
Long Term Trading Analysis for (ARQT) - Stock Traders Daily
Arcutis Biotherapeutics: +200% On ZORYVE Approval, But When Is The Next Leg Up? - Seeking Alpha
Arcutis Biotherapeutics director sells $94,238 in stock By Investing.com - Investing.com Australia
Insider Selling: Director Terrie Curran Sells Shares of Arcutis Biotherapeutics Inc (ARQT) - GuruFocus.com
Arcutis Biotherapeutics director sells $94,238 in stock - Investing.com
Rubric Capital Management LP's Strategic Acquisition in Arcutis Biotherapeutics Inc - GuruFocus.com
Arcutis' ZORYVE® (roflumilast) Awarded Best Eczema Treatment by Glamour - The Manila Times
Arcutis' ZORYVE Wins Glamour's Best Eczema Treatment Award, Targets 26M Patient Market | ARQT Stock News - StockTitan
GSA Capital Partners LLP Has $2.21 Million Position in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) - MarketBeat
Chronic Hand Eczema Pipeline Update 2024: FDA Approvals, - openPR
Wall Street Analysts See a 70.33% Upside in Arcutis Biotherapeutics (ARQT): Can the Stock Really Move This High? - Yahoo Finance
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q3 2024 Earnings Call Transcript - Insider Monkey
Arcutis Biotherapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Earnings call: Arcutis Biotherapeutics reports robust growth for ZORYVE - Investing.com
Arcutis Biotherapeutics (NASDAQ:ARQT) Earns "Buy" Rating from Needham & Company LLC - MarketBeat
Arcutis Biotherapeutics Inc (ARQT) Q3 2024 Earnings Call Highlig - GuruFocus.com
Arcutis Biotherapeutics Inc (ARQT) Q3 2024 Earnings Call Highlights: Robust Growth and ... - Yahoo Finance
Arcutis Biotherapeutics Reports Strong Q3 2024 Results - TipRanks
Morgan Stanley's Strategic Reduction in Arcutis Biotherapeutics Holdings - GuruFocus.com
Arcutis Biotherapeutics Inc (ARQT) Q3 2024 Earnings: Revenue Sur - GuruFocus.com
Arcutis Announces Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times
Arcutis Biotherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Arcutis Q3 Revenue Soars 452% to $44.8M, ZORYVE Sales Surge Amid FDA Progress | ARQT Stock News - StockTitan
High Growth Tech Stocks In The United States To Watch - Simply Wall St
Arcutis Biotherapeutics exec sells $43,551 in stock - Investing.com India
Trend Tracker for (ARQT) - Stock Traders Daily
Arcutis biotherapeutics CMO sells $134,092 in stock - Investing.com India
Arcutis Biotherapeutics director sells $86,541 in stock - Investing.com
Arcutis biotherapeutics CMO sells $134,092 in stock By Investing.com - Investing.com UK
Earnings To Watch: Arcutis Biotherapeutics Inc (ARQT) Reports Q3 2024 Result - GuruFocus.com
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - XM
abrdn plc Buys 333,200 Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) - MarketBeat
Arcutis Biotherapeutics (NASDAQ:ARQT) Trading 8.7% HigherHere's Why - MarketBeat
AMI Asset Management Corp Buys 59,487 Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) - MarketBeat
Arcutis Biotherapeutics, Inc. (ARQT) May Report Negative Earnings: Know the Trend Ahead of Q3 Release - MSN
Jefferies Initiates Coverage of Arcutis Biotherapeutics (ARQT) with Buy Recommendation - MSN
Arcutis Presents Positive Patient-Reported Outcome Data for ZORYVE® (Roflumilast) Cream 0.15% in Atopic Dermatitis at American College of Allergy, Asthma and Immunology 2024 Annual Scientific Meeting - StockTitan
Arcutis to Report Third Quarter 2024 Financial Results and Participate in an Upcoming Investor Conference - The Manila Times
Arcutis Biotherapeutics Inc (ARQT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.42%
0.16%
자본화:
|
볼륨(24시간):